Health-related quality of life analysis in stage III melanoma patients treated with adjuvant dendritic cell therapy.
Martine BloemendalMark J A RietveldW W van WilligenW R GerritsenCarl G FigdorJohannes J BonenkampHarm WestdorpSteve BoudewijnsRutger H T KoornstraEddy M M AdangGhaith BakdashPetronella B OttevangerIngrid Jolanda M De VriesKalijn Fredrike BolPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2018)
This is the first description of HRQoL in melanoma patients receiving dendritic cell vaccination. We show the expected improvement in global health status after surgical treatment of stage III melanoma. Thus, adjuvant dendritic cell vaccination does not seem to hamper this improvement, as shown in our small explorative study.